Addendum

Garadacimab (hereditary angioedema) – Addendum to Project A25-41

Report documents

Indication:

For routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older

Result of dossier assessment:

Unchanged after addendum: hint of considerable added benefit

2025-08-21 A G-BA decision was published.

Project no.: A25-94
Commission: Commission awarded on 08.07.2025 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Immune system and infections
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://doi.org/10.60584/A25-94_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.